iBio (IBIO) Raw Materials (2021 - 2022)

iBio's (IBIO) quarterly Raw Materials came in at $3.9 million in Q2 2022, up 18.67% on a QoQ basis from $3.3 million in Q1 2022.

iBio (IBIO) Raw Materials (2021 - 2022) Analysis & Trends

iBio (IBIO) has 2 years of Raw Materials data on file, last reported at $3.9 million in Q2 2022.

On a quarterly basis, Raw Materials changed N/A year-over-year to $3.9 million in Q2 2022; TTM through Jun 2022 was $3.9 million, a N/A change from a year earlier, with the FY2022 full-year figure at $3.9 million, changed N/A from the prior year.
Raw Materials for Q2 2022 stood at $3.9 million, up from $3.3 million in the prior quarter.
Over the last five years, Raw Materials for IBIO reached as high as $3.9 million in Q2 2022 and fell as low as $487000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	iBio	172.22 Mn	172.22 Mn	-

Download Data